Widespread, increasing antibiotic resistance amongst the major respiratory pathogens has
compromised traditional therapy of the major infective respiratory syndromes, including …

The costs of chronic obstructive pulmonary disease (COPD) pose a major economic burden
to the United States. Studies evaluating COPD costs have generated widely variable …

This document is an update of the original 1993 statement on community-acquired
pneumonia, incorporating new information about bacteriology, patient stratification …

Now in its third edition, this comprehensive volume is recognized as the most authoritative
review of the epidemiology of infectious disease. Divided into five sections that cover …

Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are a leading
cause of hospitalizations in the United States and the major cost driver of COPD. This study …

OBJECTIVE: This meta-analysis was performed to assess the possible prophylactic benefit
of prolonged treatment with oral N-acetylcysteine (NAC) in chronic bronchitis (CB) based on …

Exacerbations are the key drivers in the costs of chronic obstructive pulmonary disease
(COPD). The objective was to examine the costs of COPD exacerbations in relation to …

Exacerbations of chronic obstructive pulmonary disease (COPD) are associated with worse
health and increased healthcare utilisation. The Inhaled Steroids in Obstructive Lung …

Background Treatment with systemic corticosteroids for exacerbations of COPD results in
improvement in clinical outcomes. On hospitalization, corticosteroids are generally …

The importance of the underlying local and systemic oxidative stress and inflammation in
chronic obstructive pulmonary disease (COPD) has long been established. In view of the …